Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.06
DVA's Cash-to-Debt is ranked lower than
68% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 0.25 vs. DVA: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
DVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.1 Max: 3.35
Current: 0.06
0.01
3.35
Equity-to-Asset 0.25
DVA's Equity-to-Asset is ranked lower than
81% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. DVA: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
DVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.24 Max: 0.62
Current: 0.25
-0.35
0.62
Debt-to-Equity 1.99
DVA's Debt-to-Equity is ranked lower than
86% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 0.62 vs. DVA: 1.99 )
Ranked among companies with meaningful Debt-to-Equity only.
DVA' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.28  Med: 2.1 Max: 18.78
Current: 1.99
-3.28
18.78
Debt-to-EBITDA 4.62
DVA's Debt-to-EBITDA is ranked lower than
64% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 2.72 vs. DVA: 4.62 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 3.61 Max: 5.24
Current: 4.62
3.1
5.24
Interest Coverage 2.84
DVA's Interest Coverage is ranked lower than
70% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 6.77 vs. DVA: 2.84 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: 5.47
Current: 2.84
2.87
5.47
Piotroski F-Score: 5
Altman Z-Score: 2.17
Beneish M-Score: -3.04
WACC vs ROIC
7.17%
9.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.57
DVA's Operating Margin % is ranked higher than
61% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 6.68 vs. DVA: 8.57 )
Ranked among companies with meaningful Operating Margin % only.
DVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 8.57
8.49
17.15
Net Margin % 4.65
DVA's Net Margin % is ranked lower than
54% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. DVA: 4.65 )
Ranked among companies with meaningful Net Margin % only.
DVA' s Net Margin % Range Over the Past 10 Years
Min: 1.96  Med: 6.31 Max: 7.1
Current: 4.65
1.96
7.1
ROE % 13.63
DVA's ROE % is ranked higher than
60% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 8.45 vs. DVA: 13.63 )
Ranked among companies with meaningful ROE % only.
DVA' s ROE % Range Over the Past 10 Years
Min: 5.37  Med: 18.33 Max: 23.21
Current: 13.63
5.37
23.21
ROA % 3.48
DVA's ROA % is ranked lower than
55% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.54 vs. DVA: 3.48 )
Ranked among companies with meaningful ROA % only.
DVA' s ROA % Range Over the Past 10 Years
Min: 1.49  Med: 4.51 Max: 5.69
Current: 3.48
1.49
5.69
ROC (Joel Greenblatt) % 27.35
DVA's ROC (Joel Greenblatt) % is ranked higher than
76% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 15.26 vs. DVA: 27.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.82  Med: 54.54 Max: 64.23
Current: 27.35
30.82
64.23
3-Year Revenue Growth Rate -1.20
DVA's 3-Year Revenue Growth Rate is ranked higher than
62% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. DVA: -1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.2  Med: 12.6 Max: 44.8
Current: -1.2
-1.2
44.8
3-Year EBITDA Growth Rate 8.60
DVA's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 6.90 vs. DVA: 8.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 14.5 Max: 98.2
Current: 8.6
-38.6
98.2
3-Year EPS without NRI Growth Rate 12.30
DVA's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. DVA: 12.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29  Med: 13.95 Max: 125.5
Current: 12.3
-29
125.5
GuruFocus has detected 4 Warning Signs with DaVita Inc DVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVA's 30-Y Financials

Financials (Next Earnings Date: 2018-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

DVA Guru Trades in Q1 2017

Paul Tudor Jones 461,620 sh (New)
Andreas Halvorsen 381,597 sh (New)
Leucadia National 7,135 sh (New)
Ray Dalio 142,304 sh (+61.26%)
Jim Simons 1,192,900 sh (+41.26%)
Mario Gabelli 22,163 sh (+2.31%)
Richard Pzena 3,327 sh (unchged)
Warren Buffett 38,565,570 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 357,208 sh (-18.93%)
Manning & Napier Advisors, Inc 172,000 sh (-40.40%)
» More
Q2 2017

DVA Guru Trades in Q2 2017

Steven Cohen 21,300 sh (New)
Manning & Napier Advisors, Inc 1,713,476 sh (+896.21%)
Mario Gabelli 22,763 sh (+2.71%)
Richard Pzena 3,398 sh (+2.13%)
Warren Buffett 38,565,570 sh (unchged)
Leucadia National Sold Out
Andreas Halvorsen Sold Out
Ray Dalio 64,486 sh (-54.68%)
Jim Simons 533,300 sh (-55.29%)
Joel Greenblatt 36,084 sh (-89.90%)
Paul Tudor Jones 8,425 sh (-98.17%)
» More
Q3 2017

DVA Guru Trades in Q3 2017

Steven Cohen 588,300 sh (+2661.97%)
Ray Dalio 354,456 sh (+449.66%)
Manning & Napier Advisors, Inc 3,588,450 sh (+109.43%)
Warren Buffett 38,565,570 sh (unchged)
Paul Tudor Jones Sold Out
Richard Pzena Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
Mario Gabelli 21,663 sh (-4.83%)
» More
Q4 2017

DVA Guru Trades in Q4 2017

Joel Greenblatt 90,175 sh (New)
Pioneer Investments 100,883 sh (New)
Paul Tudor Jones 18,264 sh (New)
Mario Gabelli 22,013 sh (+1.62%)
Warren Buffett 38,565,570 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-12-31 New Buy0.09%$53.89 - $72.36 $ 73.6520%90,175
Mario Gabelli 2017-12-31 Add 1.62%$53.89 - $72.36 $ 73.6520%22,013
Mario Gabelli 2017-09-30 Reduce -4.83%$56.13 - $66.42 $ 73.6522%21,663
Joel Greenblatt 2017-09-30 Sold Out 0.03%$56.13 - $66.42 $ 73.6522%0
Richard Pzena 2017-09-30 Sold Out $56.13 - $66.42 $ 73.6522%0
Joel Greenblatt 2017-06-30 Reduce -89.90%0.28%$62.09 - $70.09 $ 73.6511%36,084
Mario Gabelli 2017-06-30 Add 2.71%$62.09 - $70.09 $ 73.6511%22,763
Richard Pzena 2017-06-30 Add 2.13%$62.09 - $70.09 $ 73.6511%3,398
Leucadia National 2017-06-30 Sold Out 0.04%$62.09 - $70.09 $ 73.6511%0
Joel Greenblatt 2017-03-31 Reduce -18.93%0.07%$62.9 - $70 $ 73.6511%357,208
Mario Gabelli 2017-03-31 Add 2.31%$62.9 - $70 $ 73.6511%22,163
Leucadia National 2017-03-31 New Buy0.04%$62.9 - $70 $ 73.6511%7,135
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:XKLS:5225, NYSE:UHS, ASX:RHC, BKK:BDMS-F, LSE:NMC, SZSE:300015, NAS:WOOF, ASX:SHL, HAM:CLS1, LSE:MDC, NYSE:EHC, NYSE:MD, NYSE:EVHC, NYSE:CHE, BKK:BH-Q, NAS:ACHC, JSE:LHC, XSGO:BANMED-SD, ASX:HSO, NYSE:AMN » details
Traded in other countries:TRL.Germany,
Headquarter Location:USA
DaVita Inc is engaged in operating kidney dialysis centers and providing related lab services in dialysis centers and in contracted hospitals across USA. It also operates other ancillary services and strategic initiatives.

DaVita is the world's second- largest dialysis provider, with most of its 2,400 clinics based in the U.S. The company treats nearly 200,000 patients with end-stage renal disease. In a 2012 deal valued at nearly $4.4 billion, DaVita merged with HealthCare Partners, one of the largest physician group managers in the U.S., which now represents approximately 25% of consolidated revenue. The medical group segment coordinates care for nearly 800,000 members with a network of thousands of physicians and specialists in California, Florida, Nevada, New Mexico, and Arizona.

Top Ranked Articles about DaVita Inc

DaVita Kidney Care Encourages Americans to Become Organ Donors
How to Generate Better Insight Ways to obtain different and improved understanding
I had the pleasure to sit down and discuss my value investing journey with a group of friends earlier this month. During the conversation, one of them asked this great question: “So how do you know that you have generated differentiated and better insight?” Read more...
The Evolution of My Research Process - Last but Not Least Last phase of my research process evolution
Phase IV B – Studying the History and the Ecosystem Read more...
The Evolution of My Research Process - Part I How my research process has changed over time
I was recently invited to visit the headquarter office of an investment research platform, whose research product I’ve been using for quite a while. I had a meeting with the product team, during which I walked through my research process and shared some feedback of their product. Read more...
Government Report Reveals Dialysis Industry Improves Patient Care
DaVita Kidney Care Promotes Heart-Healthy Lifestyles During American Heart Month
DaVita Inc. Schedules 4th Quarter 2017 Investor Conference Call
The Everett Clinic Announces Senior Leadership Transitions
DaVita Recognized as a Top Green Company by Newsweek
DaVita Named Inaugural Member of Bloomberg Gender-Equality Index 2018

Ratios

vs
industry
vs
history
PE Ratio 21.41
DVA's PE Ratio is ranked lower than
51% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 27.77 vs. DVA: 21.41 )
Ranked among companies with meaningful PE Ratio only.
DVA' s PE Ratio Range Over the Past 10 Years
Min: 8.64  Med: 18.16 Max: 58.72
Current: 21.41
8.64
58.72
Forward PE Ratio 18.42
DVA's Forward PE Ratio is ranked higher than
53% of the 57 Companies
in the Global Medical Care industry.

( Industry Median: 18.76 vs. DVA: 18.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.79
DVA's PE Ratio without NRI is ranked lower than
52% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 27.25 vs. DVA: 27.79 )
Ranked among companies with meaningful PE Ratio without NRI only.
DVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.64  Med: 18.14 Max: 58.72
Current: 27.79
8.64
58.72
PB Ratio 2.87
DVA's PB Ratio is ranked lower than
59% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 2.52 vs. DVA: 2.87 )
Ranked among companies with meaningful PB Ratio only.
DVA' s PB Ratio Range Over the Past 10 Years
Min: 2.11  Med: 3.14 Max: 4.47
Current: 2.87
2.11
4.47
PS Ratio 0.99
DVA's PS Ratio is ranked higher than
72% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. DVA: 0.99 )
Ranked among companies with meaningful PS Ratio only.
DVA' s PS Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.13 Max: 1.45
Current: 0.99
0.7
1.45
Price-to-Free-Cash-Flow 14.14
DVA's Price-to-Free-Cash-Flow is ranked higher than
82% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 22.88 vs. DVA: 14.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.51  Med: 14.27 Max: 42.42
Current: 14.14
7.51
42.42
Price-to-Operating-Cash-Flow 7.39
DVA's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 14.54 vs. DVA: 7.39 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.18  Med: 8.67 Max: 15.89
Current: 7.39
5.18
15.89
EV-to-EBIT 18.03
DVA's EV-to-EBIT is ranked higher than
73% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 21.25 vs. DVA: 18.03 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 11.8 Max: 20.3
Current: 18.03
6.8
20.3
EV-to-EBITDA 11.09
DVA's EV-to-EBITDA is ranked higher than
80% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 14.53 vs. DVA: 11.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 9.1 Max: 14.4
Current: 11.09
5.5
14.4
EV-to-Revenue 1.57
DVA's EV-to-Revenue is ranked higher than
68% of the 271 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. DVA: 1.57 )
Ranked among companies with meaningful EV-to-Revenue only.
DVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 1.7 Max: 2.5
Current: 1.57
1.1
2.5
PEG Ratio 3.09
DVA's PEG Ratio is ranked lower than
59% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 3.02 vs. DVA: 3.09 )
Ranked among companies with meaningful PEG Ratio only.
DVA' s PEG Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.59 Max: 5.59
Current: 3.09
0.4
5.59
Shiller PE Ratio 26.38
DVA's Shiller PE Ratio is ranked higher than
66% of the 61 Companies
in the Global Medical Care industry.

( Industry Median: 30.03 vs. DVA: 26.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
DVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.78  Med: 28.65 Max: 50.42
Current: 26.38
19.78
50.42
Current Ratio 2.88
DVA's Current Ratio is ranked higher than
55% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. DVA: 2.88 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.83 Max: 4.1
Current: 2.88
0.39
4.1
Quick Ratio 2.82
DVA's Quick Ratio is ranked higher than
57% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.21 vs. DVA: 2.82 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.75 Max: 4.1
Current: 2.82
0.37
4.1
Days Inventory 6.11
DVA's Days Inventory is ranked higher than
83% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.60 vs. DVA: 6.11 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.28
Current: 6.11
3.72
8.28
Days Sales Outstanding 43.83
DVA's Days Sales Outstanding is ranked lower than
61% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 40.49 vs. DVA: 43.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 59.55 Max: 69.35
Current: 43.83
43.53
69.35
Days Payable 17.78
DVA's Days Payable is ranked lower than
76% of the 168 Companies
in the Global Medical Care industry.

( Industry Median: 49.56 vs. DVA: 17.78 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 19.24 Max: 27.07
Current: 17.78
14.92
27.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.40
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.30 vs. DVA: 5.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.4  Med: -0.7 Max: 9.3
Current: 5.4
-58.4
9.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.00
DVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. DVA: 1.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.14 Max: 4.08
Current: 1
0.75
4.08
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.19
DVA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
71% of the 35 Companies
in the Global Medical Care industry.

( Industry Median: 1.62 vs. DVA: 2.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
DVA' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.61  Med: 1.31 Max: 4.69
Current: 2.19
0.61
4.69
Price-to-Median-PS-Value 0.88
DVA's Price-to-Median-PS-Value is ranked higher than
69% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 1.01 vs. DVA: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.04 Max: 2.09
Current: 0.88
0.35
2.09
Price-to-Peter-Lynch-Fair-Value 3.30
DVA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
58% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. DVA: 3.30 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DVA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.39 Max: 8.16
Current: 3.3
0.56
8.16
Earnings Yield (Greenblatt) % 5.55
DVA's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.86 vs. DVA: 5.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.5 Max: 14.6
Current: 5.55
4.9
14.6
Forward Rate of Return (Yacktman) % 14.61
DVA's Forward Rate of Return (Yacktman) % is ranked higher than
73% of the 131 Companies
in the Global Medical Care industry.

( Industry Median: 9.05 vs. DVA: 14.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.5  Med: 18.3 Max: 35.4
Current: 14.61
12.5
35.4

More Statistics

Revenue (TTM) (Mil) $14,278.50
EPS (TTM) $ 3.44
Beta1.14
Short Percentage of Float2.66%
52-Week Range $52.51 - 80.71
Shares Outstanding (Mil)182.46

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 16,201 16,951
EBIT (Mil $)
EBITDA (Mil $) 2,533 2,713
EPS ($) 4.03 4.90
EPS without NRI ($) 4.03 4.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.76%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}